Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 938

1.

HDAC3 regulates DNMT1 expression in multiple myeloma: Therapeutic implications.

Harada T, Ohguchi H, Grondin Y, Kikuchi S, Sagawa M, Tai YT, Mazitschek R, Hideshima T, Anderson KC.

Leukemia. 2017 May 11. doi: 10.1038/leu.2017.144. [Epub ahead of print]

PMID:
28490812
2.

KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival.

Ohguchi H, Harada T, Sagawa M, Kikuchi S, Tai YT, Richardson PG, Hideshima T, Anderson KC.

Leukemia. 2017 May 10. doi: 10.1038/leu.2017.141. [Epub ahead of print]

PMID:
28487543
3.

A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis, and cancer stem-like cells.

Ray A, Das DS, Song Y, Macri V, Richardson P, Brooks CL, Chauhan D, Anderson KC.

Leukemia. 2017 May 8. doi: 10.1038/leu.2017.135. [Epub ahead of print]

PMID:
28479592
4.

A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.

Laubach JP, Moslehi JJ, Francis SA, San Miguel JF, Sonneveld P, Orlowski RZ, Moreau P, RosiƱol L, Faber EA Jr, Voorhees P, Mateos MV, Marquez L, Feng H, Desai A, van de Velde H, Elliott J, Shi H, Dow E, Jobanputra N, Esseltine DL, Niculescu L, Anderson KC, Lonial S, Richardson PG.

Br J Haematol. 2017 May 3. doi: 10.1111/bjh.14708. [Epub ahead of print]

PMID:
28466536
5.

Ribonucleotide reductase large subunit (RRM1) as a novel therapeutic target in multiple myeloma.

Sagawa M, Ohguchi H, Harada T, Samur MK, Tai YT, Munshi NC, Kizaki M, Hideshima T, Anderson KC.

Clin Cancer Res. 2017 Apr 25. pii: clincanres.0263.2017. doi: 10.1158/1078-0432.CCR-17-0263. [Epub ahead of print]

PMID:
28442502
6.

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.

Anderson KC, Auclair D, Kelloff GJ, Sigman CC, Avet-Loiseau H, Farrell AT, Gormley NJ, Kumar SK, Landgren O, Munshi NC, Cavo M, Davies FE, Di Bacco A, Dickey JS, Gutman SI, Higley HR, Hussein MA, Jessup JM, Kirsch IR, Little RF, Loberg RD, Lohr JG, Mukundan L, Omel JL, Pugh TJ, Reaman GH, Robbins MD, Sasser AK, Valente N, Zamagni E.

Clin Cancer Res. 2017 Apr 20. pii: clincanres.2895.2016. doi: 10.1158/1078-0432.CCR-16-2895. [Epub ahead of print]

PMID:
28428191
7.

The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma.

Mishima Y, Paiva B, Shi J, Park J, Manier S, Takagi S, Massoud M, Perilla-Glen A, Aljawai Y, Huynh D, Roccaro AM, Sacco A, Capelletti M, Detappe A, Alignani D, Anderson KC, Munshi NC, Prosper F, Lohr JG, Ha G, Freeman SS, Van Allen EM, Adalsteinsson VA, Michor F, San Miguel JF, Ghobrial IM.

Cell Rep. 2017 Apr 4;19(1):218-224. doi: 10.1016/j.celrep.2017.03.025.

8.

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L, Roussel M, Payen C, Mathiot C, Fermand JP, Meuleman N, Rollet S, Maglio ME, Zeytoonjian AA, Weller EA, Munshi N, Anderson KC, Richardson PG, Facon T, Avet-Loiseau H, Harousseau JL, Moreau P; IFM 2009 Study..

N Engl J Med. 2017 Apr 6;376(14):1311-1320. doi: 10.1056/NEJMoa1611750.

PMID:
28379796
9.

Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group.

Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, Usmani SZ, Vesole DH, San-Miguel J, Kumar SK, Richardson PG, Mikhael JR, da Costa FL, Dimopoulos MA, Zingaretti C, Abildgaard N, Goldschmidt H, Orlowski RZ, Chng WJ, Einsele H, Lonial S, Barlogie B, Anderson KC, Rajkumar SV, Durie BGM, Zamagni E.

Lancet Oncol. 2017 Apr;18(4):e206-e217. doi: 10.1016/S1470-2045(17)30189-4. Review.

PMID:
28368259
10.

Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu.

Zhang L, Tai YT, Ho M, Xing L, Chauhan D, Gang A, Qiu L, Anderson KC.

Blood Cancer J. 2017 Mar 24;7(3):e547. doi: 10.1038/bcj.2017.24. No abstract available.

11.

Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells.

Das DS, Das A, Ray A, Song Y, Samur MK, Munshi NC, Chauhan D, Anderson KC.

Clin Cancer Res. 2017 Mar 7. doi: 10.1158/1078-0432.CCR-16-2692. [Epub ahead of print]

PMID:
28270494
12.

Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.

Feng X, Zhang L, Acharya C, An G, Wen K, Qiu L, Munshi NC, Tai YT, Anderson KC.

Clin Cancer Res. 2017 Mar 1. doi: 10.1158/1078-0432.CCR-16-3192. [Epub ahead of print]

PMID:
28249894
13.

Immune Therapies in Multiple Myeloma.

Kumar SK, Anderson KC.

Clin Cancer Res. 2016 Nov 15;22(22):5453-5460. doi: 10.1158/1078-0432.CCR-16-0868.

PMID:
28151713
14.

Progress and Paradigms in Multiple Myeloma.

Anderson KC.

Clin Cancer Res. 2016 Nov 15;22(22):5419-5427. doi: 10.1158/1078-0432.CCR-16-0625.

PMID:
28151709
15.

Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.

Bar-Natan M, Stroopinsky D, Luptakova K, Coll MD, Apel A, Rajabi H, Pyzer AR, Palmer K, Reagan MR, Nahas MR, Karp Leaf R, Jain S, Arnason J, Ghobrial IM, Anderson KC, Kufe D, Rosenblatt J, Avigan D.

Br J Haematol. 2017 Mar;176(6):929-938. doi: 10.1111/bjh.14493. Epub 2017 Jan 20.

PMID:
28107546
16.

Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma.

Fulciniti M, Martinez-Lopez J, Senapedis W, Oliva S, Lakshmi Bandi R, Amodio N, Xu Y, Szalat R, Gulla A, Samur MK, Roccaro A, Linares M, Cea M, Baloglu E, Argueta C, Landesman Y, Shacham S, Liu S, Schenone M, Wu SL, Karger B, Prabhala R, Anderson KC, Munshi NC.

Blood. 2017 Apr 20;129(16):2233-2245. doi: 10.1182/blood-2016-06-724831. Epub 2017 Jan 17.

PMID:
28096095
17.

p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma.

Hideshima T, Cottini F, Nozawa Y, Seo HS, Ohguchi H, Samur MK, Cirstea D, Mimura N, Iwasawa Y, Richardson PG, Munshi NC, Chauhan D, Massefski W, Utsugi T, Dhe-Paganon S, Anderson KC.

Blood. 2017 Mar 9;129(10):1308-1319. doi: 10.1182/blood-2016-09-738500. Epub 2017 Jan 12.

PMID:
28082445
18.

A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.

Hipp S, Tai YT, Blanset D, Deegen P, Wahl J, Thomas O, Rattel B, Adam PJ, Anderson KC, Friedrich M.

Leukemia. 2017 Jan 13. doi: 10.1038/leu.2016.388. [Epub ahead of print]

PMID:
28025583
19.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.

Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV.

J Immunother Cancer. 2016 Dec 20;4:90. doi: 10.1186/s40425-016-0188-z. eCollection 2016.

20.

Second primary malignancies in multiple myeloma: an overview and IMWG consensus.

Musto P, Anderson KC, Attal M, Richardson PG, Badros A, Hou J, Comenzo R, Du J, Durie BGM, San Miguel J, Einsele H, Chen WM, Garderet L, Pietrantuono G, Hillengass J, Kyle RA, Moreau P, Lahuerta JJ, Landgren O, Ludwig H, Larocca A, Mahindra A, Cavo M, Mazumder A, McCarthy PL, Nouel A, Rajkumar SV, Reiman A, Serra ER, Sezer O, Terpos E, Turesson I, Usmani S, Weiss BM, Palumbo A; International Myeloma Working Group..

Ann Oncol. 2017 Feb 1;28(2):228-245. doi: 10.1093/annonc/mdw606.

PMID:
27864218

Supplemental Content

Loading ...
Support Center